AbbVie (4AB0) Stock Overview

A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. More details

4AB0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	2/6
Dividends	4/6

Rewards

Trading at 43.6% below our estimate of its fair value

Earnings are forecast to grow 22.49% per year

Risk Analysis

Has a high level of debt

Volatile share price over the past 3 months compared to the German market

Negative shareholders equity

Large one-off items impacting financial results

+ 1 more risk

4AB0 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

4.1k

US$21.53

67.7% undervalued

stuart_roberts's Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

AbbVie Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for AbbVie
Historical stock prices
Current Share Price	US$19.80
52 Week High	US$22.00
52 Week Low	US$14.40
Beta	0.33
1 Month Change	10.00%
3 Month Change	5.88%
1 Year Change	4.76%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	23.39%

Recent updates

Shareholder Returns

	4AB0	DE Biotechs	DE Market
7D	1.5%	7.7%	0.2%
1Y	4.8%	3.8%	2.1%

Return vs Industry: 4AB0 exceeded the German Biotechs industry which returned 1.4% over the past year.

Return vs Market: 4AB0 exceeded the German Market which returned -1.6% over the past year.

Price Volatility

Is 4AB0's price volatile compared to industry and market?
4AB0 volatility
4AB0 Average Weekly Movement	10.5%
Biotechs Industry Average Movement	10.3%
Market Average Movement	5.7%
10% most volatile stocks in DE Market	14.4%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: 4AB0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 4AB0's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2012	57,000	Robert Michael	www.abbvie.com

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.

AbbVie Inc. Fundamentals Summary

How do AbbVie's earnings and revenue compare to its market cap?
4AB0 fundamental statistics
Market cap	€346.27b
Earnings (TTM)	€3.60b
Revenue (TTM)	€52.66b

95.9x

P/E Ratio

6.6x

P/S Ratio

Is 4AB0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4AB0 income statement (TTM)
Revenue	US$61.16b
Cost of Revenue	US$17.36b
Gross Profit	US$43.80b
Other Expenses	US$39.62b
Earnings	US$4.19b

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	2.37
Gross Margin	71.62%
Net Profit Margin	6.84%
Debt/Equity Ratio	-2,090.3%

How did 4AB0 perform over the long term?

See historical performance and comparison

Dividends

3.0%

Current Dividend Yield

281%

Payout Ratio

Does 4AB0 pay a reliable dividends?

See 4AB0 dividend history and benchmarks

When do you need to buy 4AB0 by to receive an upcoming dividend?
AbbVie dividend dates
Ex Dividend Date	Apr 15 2026
Dividend Pay Date	May 25 2026
Days until Ex dividend	34 days
Days until Dividend pay date	74 days

Does 4AB0 pay a reliable dividends?

See 4AB0 dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/10 12:21
End of Day Share Price	2026/03/10 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AbbVie Inc. is covered by 49 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Emily Field	Barclays
Luisa Hector	Berenberg

AbbVie (4AB0) Stock Overview

Rewards

Risk Analysis

Looking to be second time lucky with a game-changing new product

AbbVie Inc. Competitors

Merck KGaA

Gilead Sciences

Amgen

Vertex Pharmaceuticals

Price History & Performance

Recent News & Updates

AbbVie Inc., Annual General Meeting, May 08, 2026

AbbVie Announces Positive Topline Results from Phase 3 Affirm Study Evaluating SKYRIZI®? (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

U.S. Food and Drug Administration Approves Combination Treatment of VENCLEXTA (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

AbbVie Inc. Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVO) in Adults and Adolescents With Vitiligo

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

AbbVie Denies Media Reports of Talks to Buy Revolution Medicines

Recent updates

AbbVie Inc., Annual General Meeting, May 08, 2026

AbbVie Announces Positive Topline Results from Phase 3 Affirm Study Evaluating SKYRIZI®? (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

U.S. Food and Drug Administration Approves Combination Treatment of VENCLEXTA (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

AbbVie Inc. Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVO) in Adults and Adolescents With Vitiligo

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

AbbVie Denies Media Reports of Talks to Buy Revolution Medicines

AbbVie Inc. to Report Q4, 2025 Results on Feb 04, 2026

Abbvie Receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus

AbbVie to Feature New Data At ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

AbbVie Corporation Announces Two Positive Updates for Canadians Living with Ulcerative Colitis

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

Abbvie Announces New 6-Month 45Mg Luprolide Acetate for Extended-Release Injectable Suspension

AbbVie Inc. Announces Launch of Second Winds

AbbVie Inc. Announces Intangible Asset Impairment for the Third Quarter Ended September 30, 2025

AbbVie Inc. Declares Increase in Quarterly Cash Dividend, Payable on February 17, 2026

AbbVie Corporation Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers

Abbvie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (Rinvoq®?) in Adult and Adolescents with Vitiligo

Abbvie Announces Positive Topline Results from the Phase 3B/4 Head-To-Head Study

AbbVie Announces U.S. Food and Drug Administration Approves Updated Indication Statement for RINVOQ®? (upadacitinib) for the Treatment of Inflammatory Bowel Disease

Abbvie to Present New Data At Esmo 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

AbbVie Announces Positive Topline Results from Phase 2 Elite Trial Evaluating OnabotulinumtoxinA (BotoX®?) for the Treatment of Upper Limb Essential Tremor

AbbVie Inc. to Report Q3, 2025 Results on Oct 31, 2025

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab Sunirine (PVEK) - an Investigational Antibody-Drug Conjugate to Treat Rare Cancer with Limited Treatment Options

AbbVie Announces UK Pricing Strategy for ELAHERE®? (Mirvetuximab Soravtansine-gynx)

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

AbbVie's VRAYLAR®? (Cariprazine) Now Publicly Reimbursed in Alberta

Abbvie Inc. Declares Quarterly Dividend, Payable on November 14, 2025

AbbVie Announces Updated Results from Phase 2 EPCORE®? NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients with Relapsed/Refractory (R) Diffuse Large B-Cell Lymphoma (DLBCL)

Abbvie Announces Positive Topline Results from Second Phase 3 Up-Aa Trial Evaluating Upadacitinib (Rinvoq®?) for Alopecia Areata

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Capstan Therapeutics, Inc.

AbbVie Reportedly in Talks to Acquire Gilgamesh in $1 Billion Deal

Abbvie Announces Positive Topline Results from Phase 3 Up-Aa Trial Evaluating Upadacitinib for Alopecia Areata

Abbvie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia

AbbVie Announces Availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada

AbbVie Inc. to Report Q2, 2025 Results on Jul 31, 2025

AbbVie Inc Declares Quarterly Cash Dividend, Payable August 15, 2025

Genentech and AbbVie Provide Update on Phase III Verona Study

U.S. FDA Approves Expanded Indication for Abbvie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

Abbvie Features New Data Across Difficult-To-Treat Solid Tumors and Blood Cancers At Asco 2025

The Gross Law Firm Files Lawsuit Against Cerevel Therapeutics Holdings, Inc

Abbvie Announces U.S. FDA Approves Emrelis for Adults with Previously Treated Advanced Non-Small Cell Lung Cancer (Nsclc) with High C-Met Protein Overexpression

AbbVie Inc. Announces U.S. Food and Drug Administration Approval for Giant Cell Arteritis

AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines

AbbVie Inc. Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis

AbbVie Inc. to Report Q1, 2025 Results on Apr 25, 2025

AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025

AbbVie Announces Final Analysis of the Confirmatory Phase 3 MIRASOL Trial Evaluating the Efficacy and Safety of ELAHERE®?

AbbVie Inc., Annual General Meeting, May 09, 2025

AbbVie Announces SKYRIZI (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®?) for the Treatment of Adults with Giant Cell Arteritis

AbbVie Inc. Announces Board Changes, Effective July 1, 2025

Abbvie Announces the U.S. Food and Drug Administration Approves Emblaveo™

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Nimble Therapeutics, Inc.

Abbvie and Regenxbio Inc. Announce Updates on the Abbv-Rgx-314 Clinical Program

AbbVie Inc. to Report Q4, 2024 Results on Jan 31, 2025

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Nimble Therapeutics, Inc. from Telegraph Hill Partners and Roche Venture Fund for $200 million.

AbbVie Inc. (NYSE:ABBV) complete the acquisition of Aliada Therapeutics, Inc. from Johnson & Johnson Innovation - JJDC, Inc., RA Capital Management, L.P., RA Ventures, OrbiMed Advisors LLC and Sanofi Ventures.

Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma

AbbVie Inc. Announces Updated Results from the Phase 1b/2 EPCORE® NHL-2 Trial Evaluating Fixed-Duration Investigational Epcoritamab

Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025